<!DOCTYPE html>
<html >

<head>

  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>Conferences 2016</title>
  <meta content="text/html; charset=UTF-8" http-equiv="Content-Type">
  <meta name="description" content="Conferences mainly regarding clinical pharmacology, pharmacometrics and medicine will be summarized here.">
  <meta name="generator" content="bookdown 0.1 and GitBook 2.6.7">

  <meta property="og:title" content="Conferences 2016" />
  <meta property="og:type" content="book" />
  <meta property="og:url" content="http://shanmdphd.github.io/Conferences/" />
  <meta property="og:image" content="http://shanmdphd.github.io/Conferences/images/cover.png" />
  <meta property="og:description" content="Conferences mainly regarding clinical pharmacology, pharmacometrics and medicine will be summarized here." />
  <meta name="github-repo" content="shanmdphd/shanmdphd.github.io" />

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Conferences 2016" />
  
  <meta name="twitter:description" content="Conferences mainly regarding clinical pharmacology, pharmacometrics and medicine will be summarized here." />
  <meta name="twitter:image" content="http://shanmdphd.github.io/Conferences/images/cover.png" />

<meta name="author" content="Sungpil Han">

<meta name="date" content="2016-10-02">

<script type="text/x-mathjax-config">
MathJax.Hub.Config({
  TeX: { equationNumbers: { autoNumber: "AMS" } }
});
</script>

  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black">
  
  
<link rel="prev" href="kscpt.html">
<link rel="next" href="acrep.html">

<script src="libs/jquery/jquery.min.js"></script>
<link href="libs/gitbook/css/style.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-fontsettings.css" rel="stylesheet" />










<link rel="stylesheet" href="css/style.css" type="text/css" />
</head>

<body>


  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="./">Conferences</a></li>

<li class="divider"></li>
<li class="chapter" data-level="1" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i><b>1</b> Introduction</a></li>
<li class="chapter" data-level="2" data-path="section-2.html"><a href="section-2.html"><i class="fa fa-check"></i><b>2</b> 심장내과</a></li>
<li class="chapter" data-level="3" data-path="-3.html"><a href="-3.html"><i class="fa fa-check"></i><b>3</b> 심장내과 3부</a></li>
<li class="chapter" data-level="4" data-path="cancer-immunotherapy.html"><a href="cancer-immunotherapy.html"><i class="fa fa-check"></i><b>4</b> Cancer immunotherapy</a></li>
<li class="chapter" data-level="5" data-path="bioimaging-2016-04-29.html"><a href="bioimaging-2016-04-29.html"><i class="fa fa-check"></i><b>5</b> Bioimaging 2016-04-29</a></li>
<li class="chapter" data-level="6" data-path="-fda-.html"><a href="-fda-.html"><i class="fa fa-check"></i><b>6</b> 신약개발을 위한 FDA의 바이오이미징 표준화 프로그램 |</a><ul>
<li class="chapter" data-level="6.1" data-path="-fda-.html"><a href="-fda-.html#-center-for-bioimaging-of-new-drug-development-amc"><i class="fa fa-check"></i><b>6.1</b> 김정곤 Center for Bioimaging of New Drug Development AMC</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="kscpt.html"><a href="kscpt.html"><i class="fa fa-check"></i><b>7</b> 2016 KSCPT</a><ul>
<li class="chapter" data-level="7.1" data-path="kscpt.html"><a href="kscpt.html#opening-remark"><i class="fa fa-check"></i><b>7.1</b> Opening Remark</a></li>
<li class="chapter" data-level="7.2" data-path="kscpt.html"><a href="kscpt.html#first-session"><i class="fa fa-check"></i><b>7.2</b> First Session</a><ul>
<li class="chapter" data-level="7.2.1" data-path="kscpt.html"><a href="kscpt.html#precision-medicine-a-clinical-pharmacological-perspective"><i class="fa fa-check"></i><b>7.2.1</b> 13:20~14:00 Precision Medicine: A Clinical Pharmacological Perspective</a></li>
<li class="chapter" data-level="7.2.2" data-path="kscpt.html"><a href="kscpt.html#the-role-of-pharmacogenomics-in-drug-development-regulatory-review-and-clinical-practice"><i class="fa fa-check"></i><b>7.2.2</b> 14:00~14:30 The role of pharmacogenomics in drug development, regulatory review and clinical practice</a></li>
<li class="chapter" data-level="7.2.3" data-path="kscpt.html"><a href="kscpt.html#the-liver-gut-microbiota-axis-modulates-inter-individual-variability-in-xenobiotic-disposition-and-toxicology"><i class="fa fa-check"></i><b>7.2.3</b> 14:30~15:00 The Liver-Gut Microbiota Axis Modulates Inter-Individual Variability in Xenobiotic Disposition and Toxicology</a></li>
</ul></li>
<li class="chapter" data-level="7.3" data-path="kscpt.html"><a href="kscpt.html#second-session"><i class="fa fa-check"></i><b>7.3</b> Second Session</a><ul>
<li class="chapter" data-level="7.3.1" data-path="kscpt.html"><a href="kscpt.html#the-role-of-stem-cells-in-discovery-and-validation-of-pharmacogenomic-markers"><i class="fa fa-check"></i><b>7.3.1</b> 15:20~15:50 The role of stem cells in discovery and validation of pharmacogenomic markers</a></li>
<li class="chapter" data-level="7.3.2" data-path="kscpt.html"><a href="kscpt.html#pharmacogenomics-and-epigenomics"><i class="fa fa-check"></i><b>7.3.2</b> 15:50~16:20 Pharmacogenomics and Epigenomics</a></li>
<li class="chapter" data-level="7.3.3" data-path="kscpt.html"><a href="kscpt.html#emerging-roles-of-human-cyp1b1-in-cancer-growth-and-metastasis"><i class="fa fa-check"></i><b>7.3.3</b> 16:20~16:50 Emerging roles of human CYP1B1 in cancer growth and metastasis</a></li>
<li class="chapter" data-level="7.3.4" data-path="kscpt.html"><a href="kscpt.html#omics-for-precision-medicine-clinical-implementation-in-oncology"><i class="fa fa-check"></i><b>7.3.4</b> 16:50~17:20 omics for precision Medicine : Clinical Implementation in oncology</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="8" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html"><i class="fa fa-check"></i><b>8</b> “Translation and Convergence for Future Medicine”</a><ul>
<li class="chapter" data-level="8.1" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#plenary-session-ii--rd-"><i class="fa fa-check"></i><b>8.1</b> Plenary Session II “의료기술및 R&amp;D 변화의최신동향”</a><ul>
<li class="chapter" data-level="8.1.1" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-1--------"><i class="fa fa-check"></i><b>8.1.1</b> 13:30 ~ 14:15 Lecture 1 :의료분야에서의 빅데이터 :임상연구 및 진료를 위한 애널리틱스의 활용</a></li>
<li class="chapter" data-level="8.1.2" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-2----"><i class="fa fa-check"></i><b>8.1.2</b> 14:15 ~ 15:00 Lecture 2 :합성 항체에서 합성 단백질로</a></li>
</ul></li>
<li class="chapter" data-level="8.2" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#parallel-session-i--chairperson--"><i class="fa fa-check"></i><b>8.2</b> Parallel Session I “의료분야에서의빅데이터” Chairperson :김태원(서울아산병원임상의학연구소장) [대강당]</a><ul>
<li class="chapter" data-level="8.2.1" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-1------alexander-turchin-harvard-university-brigham-and-womens-hospital-usa"><i class="fa fa-check"></i><b>8.2.1</b> Lecture 1 :전자의무기록에 기반한 임상 빅데이터 연구 Alexander Turchin (Harvard University, Brigham and Women’s Hospital, USA)</a></li>
<li class="chapter" data-level="8.2.2" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-2----tom-lawry-microsoft-corp.-usa"><i class="fa fa-check"></i><b>8.2.2</b> Lecture 2 : 의료분야에서의 빅데이터 분석 Tom Lawry (Microsoft Corp., USA)</a></li>
<li class="chapter" data-level="8.2.3" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-3-------"><i class="fa fa-check"></i><b>8.2.3</b> Lecture 3 :생물기작 기반 암 오믹스 데이터 분석 기법</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="9" data-path="acrep.html"><a href="acrep.html"><i class="fa fa-check"></i><b>9</b> ACREP</a><ul>
<li class="chapter" data-level="9.1" data-path="acrep.html"><a href="acrep.html#observational-study"><i class="fa fa-check"></i><b>9.1</b> Observational Study</a><ul>
<li class="chapter" data-level="9.1.1" data-path="acrep.html"><a href="acrep.html#contents"><i class="fa fa-check"></i><b>9.1.1</b> Contents</a></li>
</ul></li>
<li class="chapter" data-level="9.2" data-path="acrep.html"><a href="acrep.html#observational-study-pitfall-----"><i class="fa fa-check"></i><b>9.2</b> Observational Study의 Pitfall 및 이를 극복하기 위한 방법</a><ul>
<li class="chapter" data-level="9.2.1" data-path="acrep.html"><a href="acrep.html#experimental-study-yes"><i class="fa fa-check"></i><b>9.2.1</b> Experimental study? Yes</a></li>
<li class="chapter" data-level="9.2.2" data-path="acrep.html"><a href="acrep.html#experimental-study-no"><i class="fa fa-check"></i><b>9.2.2</b> Experimental study? No</a></li>
<li class="chapter" data-level="9.2.3" data-path="acrep.html"><a href="acrep.html#contents-1"><i class="fa fa-check"></i><b>9.2.3</b> Contents</a></li>
<li class="chapter" data-level="9.2.4" data-path="acrep.html"><a href="acrep.html#conclusion"><i class="fa fa-check"></i><b>9.2.4</b> Conclusion</a></li>
</ul></li>
<li class="chapter" data-level="9.3" data-path="acrep.html"><a href="acrep.html#diagnostic-test-biomarker-study"><i class="fa fa-check"></i><b>9.3</b> Diagnostic test &amp; Biomarker Study</a><ul>
<li class="chapter" data-level="9.3.1" data-path="acrep.html"><a href="acrep.html#contents---diagnostic-test"><i class="fa fa-check"></i><b>9.3.1</b> Contents - Diagnostic test</a></li>
<li class="chapter" data-level="9.3.2" data-path="acrep.html"><a href="acrep.html#contents---biomarker"><i class="fa fa-check"></i><b>9.3.2</b> Contents - Biomarker</a></li>
</ul></li>
<li class="chapter" data-level="9.4" data-path="acrep.html"><a href="acrep.html#----"><i class="fa fa-check"></i><b>9.4</b> 2차 자료원을 이용한 역학 연구군</a></li>
<li class="chapter" data-level="9.5" data-path="acrep.html"><a href="acrep.html#----clinical-prediction-model-individual-riskoutcome-probability--"><i class="fa fa-check"></i><b>9.5</b> 대규모 이차 자료원을 이용한 clinical prediction model : individual risk/outcome probability 예측 분석법</a></li>
<li class="chapter" data-level="9.6" data-path="acrep.html"><a href="acrep.html#web-r.org"><i class="fa fa-check"></i><b>9.6</b> Web-r.org</a><ul>
<li class="chapter" data-level="9.6.1" data-path="acrep.html"><a href="acrep.html#contents-2"><i class="fa fa-check"></i><b>9.6.1</b> Contents</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="10" data-path="prism-2016.html"><a href="prism-2016.html"><i class="fa fa-check"></i><b>10</b> Prism 2016</a><ul>
<li class="chapter" data-level="10.1" data-path="prism-2016.html"><a href="prism-2016.html#morning-session"><i class="fa fa-check"></i><b>10.1</b> Morning Session</a><ul>
<li class="chapter" data-level="10.1.1" data-path="prism-2016.html"><a href="prism-2016.html#lim-covariate-model"><i class="fa fa-check"></i><b>10.1.1</b> Lim Covariate model</a></li>
<li class="chapter" data-level="10.1.2" data-path="prism-2016.html"><a href="prism-2016.html#fda---lee"><i class="fa fa-check"></i><b>10.1.2</b> FDA - Lee</a></li>
<li class="chapter" data-level="10.1.3" data-path="prism-2016.html"><a href="prism-2016.html#pfizer"><i class="fa fa-check"></i><b>10.1.3</b> Pfizer</a></li>
</ul></li>
<li class="chapter" data-level="10.2" data-path="prism-2016.html"><a href="prism-2016.html#afternoon-session"><i class="fa fa-check"></i><b>10.2</b> Afternoon Session</a><ul>
<li class="chapter" data-level="10.2.1" data-path="prism-2016.html"><a href="prism-2016.html#kim"><i class="fa fa-check"></i><b>10.2.1</b> Kim</a></li>
<li class="chapter" data-level="10.2.2" data-path="prism-2016.html"><a href="prism-2016.html#strategic-application-of-pm-in-global-drug-development-experience-from-hanmi"><i class="fa fa-check"></i><b>10.2.2</b> Strategic application of PM in global drug development: Experience from Hanmi</a></li>
<li class="chapter" data-level="10.2.3" data-path="prism-2016.html"><a href="prism-2016.html#mbdd"><i class="fa fa-check"></i><b>10.2.3</b> MBDD</a></li>
<li class="chapter" data-level="10.2.4" data-path="prism-2016.html"><a href="prism-2016.html#pharmacometric-information-in-drug-label"><i class="fa fa-check"></i><b>10.2.4</b> Pharmacometric information in drug label</a></li>
<li class="chapter" data-level="10.2.5" data-path="prism-2016.html"><a href="prism-2016.html#pharmacometrics-in-dose-optimization"><i class="fa fa-check"></i><b>10.2.5</b> Pharmacometrics in Dose Optimization</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="11" data-path="MFDS.html"><a href="MFDS.html"><i class="fa fa-check"></i><b>11</b> MFDS-Asan Joint Symposium on Rare Diseases 2016</a><ul>
<li class="chapter" data-level="11.1" data-path="MFDS.html"><a href="MFDS.html#session-1-rare-diseases-in-korea-status-research-experiences"><i class="fa fa-check"></i><b>11.1</b> Session 1 Rare diseases in Korea : Status &amp; Research experiences</a><ul>
<li class="chapter" data-level="11.1.1" data-path="MFDS.html"><a href="MFDS.html#national-support-for-rare-disease-current-status-and-future-prospects"><i class="fa fa-check"></i><b>11.1.1</b> National support for rare disease : Current status and future prospects</a></li>
<li class="chapter" data-level="11.1.2" data-path="MFDS.html"><a href="MFDS.html#translational-research-for-drug-development-historical-perspective"><i class="fa fa-check"></i><b>11.1.2</b> Translational research for drug development : Historical perspective</a></li>
</ul></li>
<li class="chapter" data-level="11.2" data-path="MFDS.html"><a href="MFDS.html#session-2-global-regulatory-experiences-in-orphan-drug-development"><i class="fa fa-check"></i><b>11.2</b> Session 2 Global regulatory experiences in orphan drug development</a><ul>
<li class="chapter" data-level="11.2.1" data-path="MFDS.html"><a href="MFDS.html#considerations-for-drug-development-for-rare-diseases-cases-of-inborn-errors-of-metabolism"><i class="fa fa-check"></i><b>11.2.1</b> Considerations for drug development for rare diseases : Cases of inborn errors of metabolism</a></li>
<li class="chapter" data-level="11.2.2" data-path="MFDS.html"><a href="MFDS.html#role-of-pharmacometrics-in-the-development-of-orphan-drugs"><i class="fa fa-check"></i><b>11.2.2</b> Role of pharmacometrics in the development of orphan drugs</a></li>
</ul></li>
<li class="chapter" data-level="11.3" data-path="MFDS.html"><a href="MFDS.html#session-3-lessons-and-learned-rd-for-rare-disease"><i class="fa fa-check"></i><b>11.3</b> Session 3 Lessons and learned : R&amp;D for rare disease</a><ul>
<li class="chapter" data-level="11.3.1" data-path="MFDS.html"><a href="MFDS.html#lessons-from-an-orphan-drug-development-i"><i class="fa fa-check"></i><b>11.3.1</b> Lessons from an orphan drug development (I)</a></li>
<li class="chapter" data-level="11.3.2" data-path="MFDS.html"><a href="MFDS.html#lessons-from-an-orphan-drug-development-ii"><i class="fa fa-check"></i><b>11.3.2</b> Lessons from an orphan drug development (II)</a></li>
<li class="chapter" data-level="11.3.3" data-path="MFDS.html"><a href="MFDS.html#case-studies-on-inflammatory-bowel-disease-asan-medical-center"><i class="fa fa-check"></i><b>11.3.3</b> Case studies on inflammatory bowel disease Asan Medical Center</a></li>
<li class="chapter" data-level="11.3.4" data-path="MFDS.html"><a href="MFDS.html#case-studies-on-drug-targets-in-rare-ultra-rare-genetic-disorders"><i class="fa fa-check"></i><b>11.3.4</b> Case studies on drug targets in rare &amp; ultra-rare genetic disorders</a></li>
</ul></li>
<li class="chapter" data-level="11.4" data-path="MFDS.html"><a href="MFDS.html#session-4-asan-initia-tives-for-rare-disease"><i class="fa fa-check"></i><b>11.4</b> Session 4 Asan initia tives for rare disease</a><ul>
<li class="chapter" data-level="11.4.1" data-path="MFDS.html"><a href="MFDS.html#leverage-big-data-to-better-understand-rare-disease-states-and-patient-needs-rare-disease-registry-research-experience"><i class="fa fa-check"></i><b>11.4.1</b> Leverage big data to better understand rare disease states and patient needs (rare disease registry &amp; research experience)</a></li>
<li class="chapter" data-level="11.4.2" data-path="MFDS.html"><a href="MFDS.html#align-commercial-and-development-team-to-forecast-success-through-prism"><i class="fa fa-check"></i><b>11.4.2</b> Align commercial and development team to forecast success through “PRISM”</a></li>
<li class="chapter" data-level="11.4.3" data-path="MFDS.html"><a href="MFDS.html#knowledge-and-perceptions-of-clinical-research-of-patients-suffering-from-rare-diseases"><i class="fa fa-check"></i><b>11.4.3</b> Knowledge and perceptions of clinical research of patients suffering from rare diseases</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="12" data-path="toxicology-2016.html"><a href="toxicology-2016.html"><i class="fa fa-check"></i><b>12</b> Toxicology 2016</a><ul>
<li class="chapter" data-level="12.1" data-path="toxicology-2016.html"><a href="toxicology-2016.html#key-links"><i class="fa fa-check"></i><b>12.1</b> Key links</a></li>
<li class="chapter" data-level="12.2" data-path="toxicology-2016.html"><a href="toxicology-2016.html#session-i-2016-08-22"><i class="fa fa-check"></i><b>12.2</b> Session I 2016-08-22</a><ul>
<li class="chapter" data-level="12.2.1" data-path="toxicology-2016.html"><a href="toxicology-2016.html#---"><i class="fa fa-check"></i><b>12.2.1</b> 독성학 개론 및 발현기전 !!!!</a></li>
<li class="chapter" data-level="12.2.2" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.2.2"><i class="fa fa-check"></i><b>12.2.2</b> 면역독성 !</a></li>
<li class="chapter" data-level="12.2.3" data-path="toxicology-2016.html"><a href="toxicology-2016.html#-"><i class="fa fa-check"></i><b>12.2.3</b> 독성시험과 통계 !!</a></li>
<li class="chapter" data-level="12.2.4" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.2.4"><i class="fa fa-check"></i><b>12.2.4</b> 독성병리 !!</a></li>
<li class="chapter" data-level="12.2.5" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.2.5</b> 비임상시험결과의 임상시험 연계 !!!!</a></li>
</ul></li>
<li class="chapter" data-level="12.3" data-path="toxicology-2016.html"><a href="toxicology-2016.html#session-ii-2016-08-23"><i class="fa fa-check"></i><b>12.3</b> Session II 2016-08-23</a><ul>
<li class="chapter" data-level="12.3.1" data-path="toxicology-2016.html"><a href="toxicology-2016.html#---"><i class="fa fa-check"></i><b>12.3.1</b> 오믹스 기반을 이용한 독성평가 !</a></li>
<li class="chapter" data-level="12.3.2" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.3.2</b> 독성동태 및 대사 !!!</a></li>
<li class="chapter" data-level="12.3.3" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.3.3</b> 유전독성 및 발암성 !!</a></li>
<li class="chapter" data-level="12.3.4" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.3.4"><i class="fa fa-check"></i><b>12.3.4</b> 신경독성 !</a></li>
<li class="chapter" data-level="12.3.5" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.3.5</b> 식품의 위해도 평가 !</a></li>
<li class="chapter" data-level="12.3.6" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.3.6"><i class="fa fa-check"></i><b>12.3.6</b> 생식발생독성 !</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="13" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><i class="fa fa-check"></i><b>13</b> 2016년 신약임상개발 전문가 과정 “Clinical Research Science Expert Course for Cutting-edge Drug Development”</a><ul>
<li class="chapter" data-level="13.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#drug-discovery-and-preclinical-candidate-selection"><i class="fa fa-check"></i><b>13.1</b> Drug discovery and preclinical candidate selection</a><ul>
<li class="chapter" data-level="13.1.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#-1st"><i class="fa fa-check"></i><b>13.1.1</b> 김재은 (1ST)</a></li>
</ul></li>
<li class="chapter" data-level="13.2" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#preclinical-development-and-ind-gono-go-decision-using-case-studies"><i class="fa fa-check"></i><b>13.2</b> Preclinical development and IND go/no-go decision (using case studies)</a></li>
<li class="chapter" data-level="13.3" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#global-drug-development-and-interaction-with-regulatory-agencies-fda-emea-using-case-studies"><i class="fa fa-check"></i><b>13.3</b> Global drug development and interaction with regulatory agencies (FDA, EMEA) (using case studies)</a></li>
<li class="chapter" data-level="13.4" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#clinical-pharmacology"><i class="fa fa-check"></i><b>13.4</b> Clinical Pharmacology</a></li>
<li class="chapter" data-level="13.5" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#the-actual-development-and-operation-of-pharmacovigillance-system-in-korean-pharmaceutical-companies"><i class="fa fa-check"></i><b>13.5</b> The actual development and operation of Pharmacovigillance system in Korean pharmaceutical companies</a><ul>
<li class="chapter" data-level="13.5.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#experience-of-sop-development-pv-training-sharing-pv-audit-finding"><i class="fa fa-check"></i><b>13.5.1</b> Experience of SOP development &amp; PV training/ Sharing PV audit finding</a></li>
<li class="chapter" data-level="13.5.2" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#establishment-and-application-of-safety-database-system"><i class="fa fa-check"></i><b>13.5.2</b> Establishment and Application of Safety Database System:</a></li>
</ul></li>
<li class="chapter" data-level="13.6" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#open-innovation-in-drug-development"><i class="fa fa-check"></i><b>13.6</b> Open innovation in drug development</a></li>
<li class="chapter" data-level="13.7" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#clinical-development-strategy-and-plan-workshop"><i class="fa fa-check"></i><b>13.7</b> Clinical development strategy and plan workshop</a><ul>
<li class="chapter" data-level="13.7.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#course-intro---understanding-tpp-and-hcv"><i class="fa fa-check"></i><b>13.7.1</b> Course intro - Understanding TPP and HCV</a></li>
<li class="chapter" data-level="13.7.2" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#candidate-selection-through-poc"><i class="fa fa-check"></i><b>13.7.2</b> Candidate selection through PoC</a></li>
<li class="chapter" data-level="13.7.3" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#late-phase-development-commercialization"><i class="fa fa-check"></i><b>13.7.3</b> Late phase Development &amp; Commercialization</a></li>
<li class="chapter" data-level="13.7.4" data-path="acrep.html"><a href="acrep.html#----"><i class="fa fa-check"></i><b>13.7.4</b> 국내 사례 소개 및 질의/응답</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="14" data-path="reference.html"><a href="reference.html"><i class="fa fa-check"></i><b>14</b> Reference</a></li>
<li class="divider"></li>
<li><a href="http://shanmdphd.github.io">Back to shanmdphd.github.io</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">Conferences 2016</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="translation-and-convergence-for-future-medicine" class="section level1">
<h1><span class="header-section-number">Chapter 8</span> “Translation and Convergence for Future Medicine”</h1>
<ul>
<li>미래 의학을 위한 중개 및 융합연구</li>
<li>Asan International Medical Symposium 2016</li>
<li>Innovative Future for Medical Science &amp; Technology -</li>
<li>2016년 6월 17일 (금) 서울아산병원 동관 6층 대강당 외 AIMS</li>
</ul>
<div id="plenary-session-ii--rd-" class="section level2">
<h2><span class="header-section-number">8.1</span> Plenary Session II “의료기술및 R&amp;D 변화의최신동향”</h2>
<ul>
<li>Chairperson :김청수(서울아산병원비뇨기과교수)</li>
</ul>
<div id="lecture-1--------" class="section level3">
<h3><span class="header-section-number">8.1.1</span> 13:30 ~ 14:15 Lecture 1 :의료분야에서의 빅데이터 :임상연구 및 진료를 위한 애널리틱스의 활용</h3>
<ul>
<li>Speaker: David W. Bates (Harvard University, Brigham and Women’s Hospital, USA)</li>
<li>Rising costs</li>
<li>Moneyball, Boston red sox, walmart, watson</li>
<li>Big data 1M - 1giga(human genome) - 1 peta</li>
<li>EHR, Genetics, Diagnostics, Mobile devices,</li>
<li>Meaningful Use - EHR - growing.</li>
<li><a href="https://www.healthit.gov/providers-professionals/meaningful-use-definition-objectives" class="uri">https://www.healthit.gov/providers-professionals/meaningful-use-definition-objectives</a></li>
<li><a href="https://healthit.gov" class="uri">https://healthit.gov</a></li>
<li>Big data concepts</li>
<li>Validation is important!</li>
<li>Big data and research - Brigham and Women’s - Pathology ePath, Immunology Big data Genomic platform</li>
<li>Essential for future approach</li>
<li>RPDR - New entity at partners healthcare = CMS, biobank, survey data, imaging, notes repo</li>
<li>Big data in clinical care</li>
<li>5% patients ~ 50% cost</li>
<li>iCMP claims-based approach - 3000 patients</li>
<li>multiple parameters - wearable devices - continuous supervision on general care floors</li>
<li>Adverse events</li>
<li>PCORnet - not popular</li>
<li>New Sources - the trajectory of mobile apps</li>
<li>Literature Review - 7301 titles and abstracts</li>
<li>App Review - iTunes, Google Play -&gt; possibly useful 16</li>
<li>Professional Society Review -</li>
<li>Ginger.io <a href="https://ginger.io/" class="uri">https://ginger.io/</a></li>
<li>to drive better health outcomes through the use of passive mobile data and behavioral analytics.</li>
<li>!!! Example projects - Predictive Modeling</li>
<li>What we need to do all these</li>
<li>Analytics tools, repo, data warehouse, epic reporting (Clarity reporting database)</li>
<li>Clinical data - ubiquitous</li>
<li>!!!!Novel sources are most likely to provide marginal improvement - social, mobile!!!!</li>
<li>Predictions / Implications</li>
<li>Transformative as the internet</li>
<li>Killer app - Google Maps</li>
</ul>
<div id="questions" class="section level4">
<h4><span class="header-section-number">8.1.1.1</span> Questions</h4>
<ul>
<li>김규표 교수님 - Social media and health care</li>
<li>김청수 교수님 - Government and insurance - reasonably difficult to acquire - costly.</li>
</ul>
</div>
</div>
<div id="lecture-2----" class="section level3">
<h3><span class="header-section-number">8.1.2</span> 14:15 ~ 15:00 Lecture 2 :합성 항체에서 합성 단백질로</h3>
<ul>
<li>Sachdev Sidhu (University of Toronto, Canada)</li>
<li>The Donnelly Centre - From systems biology to systematic treatment</li>
<li>Therapeutic antibody revolution - highly versatile, numorous diseases</li>
<li>Ab-durg conjugates, fragment, bispecific, engineered cells</li>
<li>Targeting cancer with antibodies</li>
<li>!!! problem - small populations - boutique treatment!!!</li>
<li>In vitro protein evolution</li>
<li>Affinity, specificity enhanced</li>
<li>Antibody molecules</li>
<li>binding site of Ab</li>
<li>highly optimized - automatic mutation of binding site</li>
<li>Toronto Synthetic Antibody Library - highly diverse - Herceptin</li>
<li>PHAGE - Genentech</li>
<li>only changed the function, not others</li>
<li>Functional genomics - <strong>Large-scale, industry-quality Ab generation</strong> - Preclinical biology | The middle was not quite available but now it’s doable.</li>
<li>Cancer Antibody TRAC antibodies - bacerial pathogens</li>
<li>High yield and high affinity Fabs from naive library - 1394 total against 80 targets</li>
<li><a href="http://sites.utoronto.ca/sidhulab/about.html" class="uri">http://sites.utoronto.ca/sidhulab/about.html</a></li>
<li>natural - synthetic Ab - synthetic proteins - synthesizable proteins</li>
<li>D-protein therapeutics.- samll proteins synthesized entirely rom D-amino acids, Ab like affinity, specificity and stability,</li>
<li>in vitro d-protein advantages - longer circulating HL than L-proteins - less immunogenicity - ersistant to metabolism in plasma</li>
</ul>
</div>
</div>
<div id="parallel-session-i--chairperson--" class="section level2">
<h2><span class="header-section-number">8.2</span> Parallel Session I “의료분야에서의빅데이터” Chairperson :김태원(서울아산병원임상의학연구소장) [대강당]</h2>
<p>15:20 ~ 18:00</p>
<div id="lecture-1------alexander-turchin-harvard-university-brigham-and-womens-hospital-usa" class="section level3">
<h3><span class="header-section-number">8.2.1</span> Lecture 1 :전자의무기록에 기반한 임상 빅데이터 연구 Alexander Turchin (Harvard University, Brigham and Women’s Hospital, USA)</h3>
<ul>
<li>Data warehouse : integrates data from multiple sources - i2b2 | ABLE | OHDSI</li>
<li>who entered the data? Wrong input to public repo (DKA for 2 years!)</li>
<li>Data quality</li>
<li>Raynaud’s syndrome - Omega3 (Failure)</li>
</ul>
</div>
<div id="lecture-2----tom-lawry-microsoft-corp.-usa" class="section level3">
<h3><span class="header-section-number">8.2.2</span> Lecture 2 : 의료분야에서의 빅데이터 분석 Tom Lawry (Microsoft Corp., USA)</h3>
<ul>
<li>8 seconds = Concentration time</li>
<li>Analytics Convergence Zone - Clinical data, Geo/Social/Environmental data/Claims&amp;Cost Data/Pharma&amp;Life Sience Data, Patient &amp; Citizen Data</li>
<li><a href="https://powerbi.microsoft.com/ko-kr/" class="uri">https://powerbi.microsoft.com/ko-kr/</a> !!!!! 반드시 사용해 볼것. 좋은 Visualization.</li>
<li><a href="http://www.ciokorea.com/news/29118" class="uri">http://www.ciokorea.com/news/29118</a></li>
</ul>
</div>
<div id="lecture-3-------" class="section level3">
<h3><span class="header-section-number">8.2.3</span> Lecture 3 :생물기작 기반 암 오믹스 데이터 분석 기법</h3>
<ul>
<li>speaker: 김 선 (서울대학교 생물정보연구소)</li>
<li><a href="https://sites.google.com/site/biohealthinformaticslab/sun-kim" class="uri">https://sites.google.com/site/biohealthinformaticslab/sun-kim</a></li>
<li><a href="http://bioinfo.snu.ac.kr/main/index.php" class="uri">http://bioinfo.snu.ac.kr/main/index.php</a></li>
<li>DNA, RNA, Protein이 중요 - Somatic mutation뿐만 아니라</li>
<li>Transcriptome (RNA-sequencing data)</li>
<li>싸고 쉽다.</li>
<li>그에 비해 Underestimated되어 있다.</li>
<li>Breast cancer</li>
<li>가장 잘 알려진 암종.</li>
<li>21-gene Oncotype DX !!! <a href="http://www.oncotypedx.com/" class="uri">http://www.oncotypedx.com/</a></li>
<li>PAM50 - Prediction analysis of microarray by 50 gene classifier !!! - Survival 예측하는 Gold-standard</li>
<li>Transcriptome Data analysis <a href="http://prosigna.com/x-us/overview/" class="uri">http://prosigna.com/x-us/overview/</a></li>
<li>Pathway (context) analysis는 과연 informative한가?</li>
<li>A Critical Evaluation of Network and Pathway-Based Classifiers for Outcome Prediction in Breast Cancer (PLoS One 2012) <a href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0034796" class="uri">http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0034796</a></li>
<li>50개를 랜덤하게 취해도 유의미하게 나왔다. 아무거나 취해도 유의미하게 만들 수 있다. (Negative result!)</li>
<li>“Based on these results there is currently no reason to prefer prognostic classifiers based on composite features over single genes classifiers for predicting outcome in breast cancer.”</li>
<li>따라서 50개를 정할 때 기능적인 면을 고려해야 한다.</li>
<li>PPI-based Pathway Decomposition !!! - 우리의 분류를 기반으로 Survival plot를 그리면 확연한 차이가 난다.</li>
<li>Decomposed pathway and its activity measurement Using RNA-sequencing data</li>
<li>이러한 알고리듬으로 RNA-sequencing data 분석 (1138개의 sample을 사용)</li>
<li>TCGA data (Breast Cancer)</li>
<li>기본적으로 information theory를 응용한 것이다.</li>
<li>Subtype과 발현량의 ranking에 따라 score를 매긴 후 distinguishing할 수 있다.</li>
<li>클래스마다 차이가 확연한 Subnetwork A는 좋은 모델</li>
<li>클래스마다 차이가 없으면 Subnetwork C는 나쁜 모델. 우리는 좋은 모델을 택해야 한다.</li>
<li><strong>Top10 Regulated pathways by TF/miRNA</strong></li>
<li>mir-30a (basal cell cycle activation) -&gt; mir-149, let-7b, mir-30a</li>
<li>Sub-network mining approach</li>
<li>Experimental validation requires collaborators who enjoy new approaches.</li>
<li>혹시 talk를 들으시고 관심있으면 Contact.</li>
</ul>
<p><a href="http://aims.amc.seoul.kr/asan/imageDown/homebuilder/20160527?fileName=Scientific-Program-kor.jpg" class="uri">http://aims.amc.seoul.kr/asan/imageDown/homebuilder/20160527?fileName=Scientific-Program-kor.jpg</a> <a href="http://www.amc.seoul.kr/asan/academy/event/eventDetail.do?eventId=572" class="uri">http://www.amc.seoul.kr/asan/academy/event/eventDetail.do?eventId=572</a> <a href="http://aims.amc.seoul.kr/asan/depts/aims/E/deptMain.do" class="uri">http://aims.amc.seoul.kr/asan/depts/aims/E/deptMain.do</a></p>

</div>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="kscpt.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="acrep.html" class="navigation navigation-next " aria-label="Next page""><i class="fa fa-angle-right"></i></a>

<script src="libs/gitbook/js/app.min.js"></script>
<script src="libs/gitbook/js/lunr.js"></script>
<script src="libs/gitbook/js/plugin-search.js"></script>
<script src="libs/gitbook/js/plugin-sharing.js"></script>
<script src="libs/gitbook/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook/js/plugin-bookdown.js"></script>
<script src="libs/gitbook/js/jquery.highlight.js"></script>
<script>
require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"facebook": true,
"twitter": true,
"google": false,
"weibo": false,
"instapper": false,
"vk": false,
"all": ["facebook", "google", "twitter", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": "https://github.com/shanmdphd/shanmdphd.github.io/edit/master/_ConferencesSource/2016-06-17-AMIS.rmd",
"text": "Edit"
},
"download": ["bookdown.pdf", "bookdown.epub", "bookdown.mobi"],
"toc": {
"collapse": "subsection"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    if (location.protocol !== "file:" && /^https?:/.test(script.src))
      script.src  = script.src.replace(/^https?:/, '');
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
